Baxter International Earnings Call: Growth Meets Margin Squeeze

Baxter International Inc ((BAX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Baxter International’s latest earnings call painted a cautious but determined picture, as solid fourth‑quarter revenue growth and strong demand in select franchises were overshadowed by sharp margin compression, an earnings miss and multiple operational headwinds. Management emphasized cost actions, a revamped operating model and gradual improvement, but signaled that meaningful margin recovery may not materialize until the back half of 2026.

Top-Line Growth in Q4

Baxter delivered Q4 2025 global sales from continuing operations of about $3.0 billion, up 8% on a reported basis and 3% operationally versus a year ago. The modest underlying growth shows the portfolio still has demand support, even as mix shifts, product issues and regional dynamics complicate the company’s profit picture.

Advanced Surgery Delivers Double-Digit Gains

Advanced Surgery once again stood out, posting $328 million in Q4 sales, up 11% year over year. Growth was driven by hemostats and sealants alongside steady procedure volumes, reinforcing this business as a key growth engine and an important offset to weaker trends in other parts of Baxter’s portfolio.

HealthCare Systems & Connectivity Builds Momentum

HealthCare Systems and Technology generated $827 million in sales, up 4%, while Care & Connectivity Solutions contributed $537 million, also up 4%. Notably, U.S. capital orders for CCS surged nearly 30% year over year, and management reported no meaningful slowdown in U.S. hospital capital spending, suggesting healthy demand for Baxter’s connectivity and monitoring solutions.

Drug Compounding Strength Offsets Pharma Soft Spots

Within Pharmaceuticals, Drug Compounding was a bright spot, growing 18% in Q4 thanks to strong demand for services outside the U.S. This performance helped partially counterbalance weakness elsewhere in the segment and highlighted the value of Baxter’s outsourcing capabilities in a constrained hospital staffing and supply environment.

Cash Generation Supports Deleveraging Plans

Free cash flow reached $456 million in the fourth quarter, lifting full‑year free cash flow to $438 million. Management reiterated that cash will be prioritized for reducing leverage and indicated that free cash flow should improve in 2026 versus 2025, albeit with a back‑half‑weighted pattern consistent with the broader earnings outlook.

New Operating Model and Baxter GPS Initiative

The company outlined a new operating model aimed at “delayering” the organization and embedding key functions directly into the businesses. Baxter also launched its Growth & Performance System and held a President’s Kaizen, initiatives designed to improve accountability, sharpen execution and accelerate both innovation and commercialization across the portfolio.

Innovation Pipeline and Upcoming Product Launches

Management highlighted several recent and pending product launches, including the Connect 360 Monitor in Front Line Care, the Dynamo series stretcher on its smart bed and stretcher platform and the PureVu system on the IQx platform expected in early Q2. Baxter reiterated its commitment to invest in R&D at or above historical levels, underscoring innovation as a pillar of long‑term growth.

Lower Interest Expense Cushions the Bottom Line

Net interest expense from continuing operations in the quarter came in at $58 million, down $32 million from the prior year period. The improvement reflects debt reduction following the sale of Vantiv, providing some relief to the income statement even as operating margins face significant pressure.

Adjusted EPS Miss Signals Ongoing Profit Pressure

Total company adjusted earnings from continuing operations were $0.44 per diluted share in Q4, falling below expectations. Looking ahead, Baxter’s full‑year 2026 adjusted EPS guidance of $1.85 to $2.05 per share underscores a modest earnings trajectory and reflects the time needed for cost actions and mix improvements to work through the system.

Gross Margin Hit by Mix, Costs and One-Offs

Adjusted gross margin from continuing operations dropped to 35.5% in Q4, a steep decline of roughly 900 basis points year over year. The deterioration was driven by unfavorable product and geographic mix, higher manufacturing and supply costs, nonrecurring inventory adjustments of about $40 million and escalating tariffs, all of which weighed heavily on profitability.

Operating and Segment Margins Under Strain

Adjusted operating margin fell 340 basis points to 11.8% in the quarter, with both major segments feeling the pinch. MPT adjusted operating margin slipped 110 basis points to 15.4%, while HST margin declined 330 basis points to 15.2%, reflecting mix shifts, inventory adjustments, higher tariffs and increased corporate allocations following the Kidney Care divestiture.

Novum Pump Disruption Clouds Revenue Visibility

Ongoing shipment and installation holds, as well as some customer returns tied to the Novum large‑volume pump, weighed on infusion pump sales in Q4. Management described varied customer reactions and baked into guidance the assumption that the ship‑and‑installation hold will last all year, introducing a notable top‑line and execution risk for 2026.

IV Solutions Demand Resets Lower in the U.S.

Baxter reported that underlying U.S. demand for IV Solutions remains below historical norms, a shift linked to fluid conservation efforts and evolving clinical practices following Hurricane Helene. The company now views this reduced demand as a new baseline for the market, implying a structurally lower growth trajectory for this historically important business.

Pharmaceuticals Segment Faces Broad-Based Weakness

Injectables and Anesthesia combined sales fell 9% to $352 million in Q4, pressured by IV push trends, supply and backorder challenges and softer demand for certain anesthesia products. The Pharmaceuticals segment posted an adjusted operating margin of just 5.8%, underscoring the urgency of addressing mix, supply resilience and commercial execution in this business.

Tariffs and Nonrecurring Costs Weigh on Margins

Management flagged tariffs as a major headwind, estimating a $130 million to $140 million impact for 2026. In addition, nonrecurring costs and around $40 million of inventory adjustments significantly pressured Q4 margins and are expected to linger into the first half of 2026 as higher‑cost inventory works through the system.

Tax Rate and Corporate Reallocations Distort Segment Margins

The adjusted tax rate for continuing operations rose to 27.2% in Q4, above the full‑year level and adding to the bottom‑line drag. Following the Kidney Care sale, corporate costs were reallocated across segments and some functional expenses were reclassified into cost of goods sold, changing the presentation of margins and R&D while increasing segment‑level allocations.

Guidance Points to Flat 2026 and Back-Half Recovery

For full‑year 2026, Baxter guided reported sales to be flat to up 1%, with foreign exchange a roughly 100‑basis‑point tailwind and MSA/Vantiv revenue a ~30‑basis‑point drag, implying essentially flat organic growth across segments. The company targets a 13%–14% adjusted operating margin, non‑operating expenses of $280 million to $300 million, a tax rate of 18.5%–19.5%, diluted shares around 518 million and adjusted EPS of $1.85–$2.05, with the toughest comparisons in Q1 and improvements weighted to the second half.

Baxter’s earnings call highlighted a business navigating a demanding transition, with healthy demand in Advanced Surgery, connectivity and compounding countered by tariff pressure, product disruptions and margin erosion. Management is leaning on cost actions, a new operating model and an active pipeline to restore profitability, but investors should expect a gradual, back‑half‑loaded recovery through 2026 rather than a quick turnaround.